SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (189)9/15/1997 7:35:00 AM
From: David Cathcart   of 1826
 
MZ

Your knowledgeable skepticism regarding MGI 114 is a valuable addition to this thread. Some of us (e.g. me) need to hear what you are saying. I hope others on this thread, who are able to discuss the dose level issue with some authority, will chime in and shed further light.

Perhaps the three cases of efficacy thus far were purely coincidental. Perhaps those conducting the phase I trial miscalculated the beginning dose. Perhaps we are not approaching a dose level in which, we are told, the corresponding amount in mice produced 100% results. Whatever the case, I understand that the dose level hit 18 mg/m^2 last week. [The expected next-level dose of 19 mg/m^2 was an approximation.] JVM said in an earlier post that, in corresponding doses, 15 mg/m^2 in mice produced 50% results and 21 mg/m^2 produced 100% results. The current dose would put us right in the middle. If you are right, there is no reason to get excited. If you are wrong, there is reason to start to take notice. If no once else can help settle the issue before then, time will tell.

MGI 114 has always been the exciting moon shot for me in this story. Salagen represents the safety net with bounce. If we miss the moon, I'll just look forward to the bounce. The bounce can be exciting all by itself.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News